國家衛生研究院 NHRI:Item 3990099045/8287
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 854148      在线人数 : 1510
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/8287


    题名: Anaplastic lymphoma kinase (ALK) inhibitors: A review of design and discovery
    作者: Wang, WC;Shiao, HY;Lee, CC;Fung, KS;Hsieh, HP
    贡献者: Institute of Biotechnology and Pharmaceutical Research
    摘要: Since the launch of Gleevec in 2001, several protein kinases have emerged as attractive therapeutic targets for the treatment of various cancers. One of these, anaplastic lymphoma kinase (ALK), has attracted a great deal of attention due to its oncogenic potential and essential role in the pathogenesis of a wide variety of human cancers, such as ALCLs, NSCLC, breast cancer, colorectal cancer, neuroblastoma, ovarian cancer, etc. To date, nine ALK inhibitors have entered clinical investigation for the treatment of cancers, including crizotinib, the first ALK inhibitor to be approved by the US FDA (in 2011) for the treatment of NSCLC patients. As resistance to crizotinib treatment has been reported in both preclinical and clinical settings, several second-generation ALK inhibitors to overcome both the wild-type and mutant ALK are being developed. In 2014, shortly after crizotinib was approved, the second-generation ALK inhibitor ceritinib was approved by the FDA. Biological activities of eight second-generation clinical ALK inhibitors are discussed in this review. Furthermore, the hit-to-drug evolution strategies used in the design of three ALK inhibitors-crizotinib, alectinib and ceritinib-are described in detail, to help medicinal chemists to understand and devise similar strategies to overcome lead development issues, such as potency, selectivity and metabolism, in the drug discovery projects.
    日期: 2014-07
    關聯: MedChemComm. 2014 Jul;5(9):1266-1279.
    Link to: http://dx.doi.org/10.1039/c4md00048j
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000341017700001
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84906534354
    显示于类别:[謝興邦] 期刊論文
    [王文傑] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    SCP84906534354.pdf848KbAdobe PDF653检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈